Enfusion, Inc. (NYSE:ENFN) Short Interest Update

Enfusion, Inc. (NYSE:ENFN) was the recipient of a significant increase in short interest in the month of January. As of January 15th, there was short interest totalling 711,700 shares, an increase of 27.9% from the December 31st total of 556,500 shares. Approximately 1.5% of the shares of the company are sold short. Based on an average daily volume of 695,500 shares, the days-to-cover ratio is presently 1.0 days.

Insiders Place Their Bets

In related news, CFO Bradley Herring sold 24,443 shares of the stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $10.61, for a total transaction of $259,340.23. Following the sale, the chief financial officer now owns 270,503 shares of the company’s stock, valued at $2,870,036.83. This represents a 8.29 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Neal Pawar sold 21,801 shares of the firm’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $10.03, for a total value of $218,664.03. Following the transaction, the chief operating officer now owns 1,143,544 shares in the company, valued at approximately $11,469,746.32. This trade represents a 1.87 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 57,367 shares of company stock valued at $591,335 over the last ninety days. 36.44% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Enfusion

Hedge funds have recently made changes to their positions in the stock. New York State Common Retirement Fund grew its holdings in Enfusion by 23.8% in the fourth quarter. New York State Common Retirement Fund now owns 1,926,968 shares of the company’s stock worth $19,848,000 after purchasing an additional 370,498 shares during the period. Rhumbline Advisers boosted its position in shares of Enfusion by 3.0% during the fourth quarter. Rhumbline Advisers now owns 62,464 shares of the company’s stock valued at $643,000 after buying an additional 1,796 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Enfusion by 612.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 208,022 shares of the company’s stock worth $1,974,000 after buying an additional 178,821 shares during the last quarter. Barclays PLC boosted its holdings in shares of Enfusion by 251.4% in the 3rd quarter. Barclays PLC now owns 86,039 shares of the company’s stock worth $817,000 after buying an additional 61,554 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Enfusion by 7.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,029,366 shares of the company’s stock worth $9,770,000 after purchasing an additional 70,367 shares during the last quarter. 81.05% of the stock is currently owned by institutional investors.

Enfusion Stock Down 0.0 %

Shares of NYSE:ENFN traded down $0.01 during trading on Monday, hitting $11.16. 791,897 shares of the company were exchanged, compared to its average volume of 1,194,758. Enfusion has a 1-year low of $7.63 and a 1-year high of $11.38. The business’s 50 day moving average is $10.55 and its 200-day moving average is $9.45. The company has a market capitalization of $1.43 billion, a P/E ratio of 278.94, a price-to-earnings-growth ratio of 1.82 and a beta of 0.96.

Analysts Set New Price Targets

A number of research analysts recently commented on ENFN shares. William Blair reaffirmed a “market perform” rating on shares of Enfusion in a research note on Monday, January 13th. Stifel Nicolaus raised their target price on Enfusion from $11.00 to $13.00 and gave the company a “buy” rating in a report on Wednesday, December 18th. Finally, Piper Sandler boosted their price target on Enfusion from $10.00 to $11.50 and gave the stock a “neutral” rating in a report on Monday, December 23rd. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, Enfusion currently has a consensus rating of “Hold” and an average price target of $10.50.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.